Plus Therapeutics, Inc. Secures $15.

Plus Therapeutics, Inc. (Nasdaq: PSTV), a U.S. clinical-stage pharmaceutical company, has secured $15.0 million in new funding from investors.

The company specializes in developing innovative, targeted radiotherapeutics designed for adults and children battling rare and difficult-to-treat cancers.

Its lead drug candidate, REYOBIQ™, is currently undergoing evaluation in the multi-center ReSPECT clinical trials.

These trials are focused on patients suffering from recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, addressing critical unmet medical needs in oncology.

This significant capital infusion underscores investor confidence in Plus Therapeutics' clinical pipeline and its approach to oncology.

The funding round provides crucial resources that will enable the company to accelerate its research and development efforts, particularly as it advances REYOBIQ™ through its ongoing clinical stages.

Securing this investment is a pivotal step for Plus Therapeutics as it continues its mission to bring novel therapeutic options to patients with challenging cancer diagnoses.

Plus Therapeutics plans to strategically deploy the $15.0 million to support the continued progression of its ReSPECT clinical trials.

This includes funding for patient enrollment, expanding trial sites, and covering operational expenses associated with clinical development.

The capital will also be instrumental in supporting regulatory activities and preparing for potential future milestones, ensuring the company can maintain momentum in its pursuit of innovative cancer treatments.

The successful completion of this funding round positions Plus Therapeutics to further strengthen its financial foundation and enhance its capabilities in the competitive biopharmaceutical landscape.

The company remains committed to its vision of transforming cancer care through targeted radiotherapeutics.

This investment is expected to facilitate the company's growth trajectory and its efforts to deliver meaningful advancements for patients facing severe and life-threatening conditions.